Avience Biomedicals (AVIENCE) Q2 FY27 Delivers Strong Q2 Growth as New Plant Nears Start
The diagnostics firm posted a 16% yearly rise in revenue and a 22% profit jump, with margins improving ahead of its new manufacturing facility's launch.
Avience Biomedicals reported robust Q2 FY27 results with revenue rising 16% year-on-year to ₹31.13 crore. Profit grew faster at 22%, and net margin expanded, as the company prepares for its new plant to begin operations.
For Avience Biomedicals, a small but ambitious diagnostics player, the second quarter was about proving growth could accelerate again after a muted second half last year. The numbers show it did, with revenue climbing 16% year-on-year and profit up 22%, as the company gears up for a pivotal capacity expansion.
The quarter saw revenue reach ₹31.13 crore, up 21% from the March quarter. Profit followed even faster, rising 32% sequentially to ₹5.54 crore. This pushed the net profit margin to 17.8%, a 140 basis-point improvement from the prior quarter.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr), Q4 FY25 (Mar 2025): 24.47
Revenue (₹ Cr), Q2 FY26 (Sep 2025): 26.82
Revenue (₹ Cr), Q4 FY26 (Mar 2026): 25.69
Revenue (₹ Cr), Q2 FY27 (Sep 2026): 31.13
Profit (₹ Cr), Q4 FY25 (Mar 2025): 4.27
Profit (₹ Cr), Q2 FY26 (Sep 2025): 4.54
Profit (₹ Cr), Q4 FY26 (Mar 2026): 4.21
Profit (₹ Cr), Q2 FY27 (Sep 2026): 5.54
Revenue (₹ Cr)
Revenue (₹ Cr), Q4 FY25 (Mar 2025): 24.47
Revenue (₹ Cr), Q2 FY26 (Sep 2025): 26.82
Revenue (₹ Cr), Q4 FY26 (Mar 2026): 25.69
Revenue (₹ Cr), Q2 FY27 (Sep 2026): 31.13
Profit (₹ Cr)
Profit (₹ Cr), Q4 FY25 (Mar 2025): 4.27
Profit (₹ Cr), Q2 FY26 (Sep 2025): 4.54
Profit (₹ Cr), Q4 FY26 (Mar 2026): 4.21
Profit (₹ Cr), Q2 FY27 (Sep 2026): 5.54
Net Profit Margin (%)
Net Profit Margin (%), Q4 FY25 (Mar 2025): 17.4
Net Profit Margin (%), Q2 FY26 (Sep 2025): 16.9
Net Profit Margin (%), Q4 FY26 (Mar 2026): 16.4
Net Profit Margin (%), Q2 FY27 (Sep 2026): 17.8
Metric
CurrentQ2 FY27 (Sep 2026)
PreviousQ4 FY26 (Mar 2026)
Revenue (₹ Cr)
31.13
25.69
Profit (₹ Cr)
5.54
4.21
Net Profit Margin (%)
17.8
16.4
The drivers behind the acceleration
Growth was supported by a large government order and improved operational leverage. Management, cited by Flash Finance, has guided for at least 60% revenue growth this fiscal year, aiming to cross ₹100 crore, backed by a current order book of ₹47 crore.
The new manufacturing facility at the YEIDA Medical Device Park is central to this plan. According to a report by Zeriq, the plant's start was planned for late October or early November 2026. Its commissioning is expected to enable participation in larger government tenders and boost export capabilities.
Margins held firm despite rising costs
Total expenses rose 23.5% quarter-on-quarter, keeping pace with the revenue surge. Yet, profitability improved, aided by a sharp 31% sequential drop in interest expense and a 768% year-on-year jump in other income. The latter, though small in absolute terms at ₹0.52 crore, provided a helpful boost.
Live Chart
· AVIENCE
(BSE)
ISIN: INE0V9I01017
A 42% yearly rise in depreciation, as reported by Flash Finance, reflects the aggressive capital expenditure for the new plant. This is a planned cost of expansion that will continue as the asset comes online.
The runway depends on execution
The company's ambitious guidance now hinges on two near-term events. As noted in the Zeriq analysis, timely commissioning of the new plant and conversion of the large ₹47 crore order book into revenue are critical. Management expects the third and fourth quarters to be much stronger as the plant runs and new product licences are utilised.
Financing the growth remains a watchpoint. The company's debt-to-equity ratio stands at 0.92, and it recently sought shareholder approval to raise its borrowing limit to ₹100 crore, as per a Flash Finance report.
Key Points
Revenue grew 16% year-on-year and 21% sequentially, signalling a re-acceleration after slower growth in the second half of FY26.
Net profit margin expanded to 17.8%, helped by lower interest costs and higher other income, despite rising depreciation from new capex.
The company's full-year guidance of 60%+ growth leans heavily on the new manufacturing facility starting up and the conversion of a ₹47 crore order book.
Working capital management and funding for expansion are key execution risks to monitor in the coming quarters.
“
Hexa Perspective
Avience Biomedicals' Q2 performance marks a positive step toward its aggressive full-year target. The improvement in margins, even as depreciation rises, shows some operating discipline during the investment phase.
The story for the next two quarters is entirely about execution. The promised growth is not yet in the numbers but sits in the pending order book and the unopened factory gates. Investors are effectively betting that the operational ramp-up will be as swift as management's guidance is bold. Any delay in the plant or order fulfilment would quickly test that faith, given the high growth expectations now priced in.
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
Frequently asked questions
What were Avience Biomedicals' Q2 FY27 results?
Avience Biomedicals reported Q2 FY27 revenue of ₹31.13 crore, a 16.1% increase year-on-year. Net profit for the quarter was ₹5.54 crore, growing 22% from the same quarter last year. The company's net profit margin improved to 17.8%.
What drove Avience Biomedicals' Q2 revenue growth?
The 21.2% quarter-on-quarter revenue growth was driven by execution on a large government order and general business growth, as the company prepares for its new manufacturing facility. Management has cited a strong order book of ₹47 crore as a key growth driver for the fiscal year.
Why did Avience Biomedicals' net profit margin improve in Q2?
Avience's net profit margin improved 140 basis points quarter-on-quarter to 17.8% despite higher expenses. This was aided by a significant 31.4% sequential drop in interest expense and higher other income, which rose sharply year-on-year to ₹0.52 crore.
What is the status of Avience Biomedicals' new manufacturing plant?
According to reports from Zeriq and Flash Finance, the new manufacturing facility at the YEIDA Medical Device Park was substantially complete. Commercial production was targeted to begin in October or early November 2026, which is expected to enable the company to bid for larger government tenders.
What is Avience Biomedicals' growth guidance for FY27?
Management has provided strong growth guidance of at least 60% for FY27, aiming to exceed ₹100 crore in revenue. This target is backed by a current order book of approximately ₹47 crore and the expected contribution from the new manufacturing facility.
What is Avience Biomedicals' current order book?
Avience Biomedicals' current order book stands at approximately ₹47 crore, as reported by Flash Finance. This represents nearly 90% of the company's total revenue from the previous financial year (FY26) and is a central pillar of its aggressive growth guidance for FY27.
Why did Avience Biomedicals' depreciation increase 41.5% year-on-year?
The 41.5% year-on-year increase in depreciation to ₹0.79 crore is due to significant capital expenditure on the new manufacturing facility. Reports from Flash Finance indicate aggressive expansion, with substantial investment in property, plant, and equipment.
What is Avience Biomedicals' debt-to-equity ratio?
Avience Biomedicals' debt-to-equity ratio is 0.92, as per the latest quality metrics. The company recently sought shareholder approval to increase its borrowing limit to ₹100 crore, according to a Flash Finance report, indicating plans to potentially raise more debt for expansion.
Did institutional investors change their stake in Avience Biomedicals recently?
Yes, according to shareholding pattern data from Laabh.com, Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) reduced their holdings significantly in the quarter ended September 2026. Meanwhile, retail investor ownership increased from 13.57% to 18.38%.
What are the key risks for Avience Biomedicals' growth?
Key risks include timely commissioning of the new plant and conversion of the ₹47 crore order book, as noted by Zeriq. Other risks are working capital funding for rapid growth, regulatory approvals for new products, and intense competition in the medical equipment sector.
Avience Biomedicals Q2 FY27 results August 2026
Avience Biomedicals announced its Q2 FY27 results for the quarter ended September 2026 in November 2026. The company reported revenue of ₹31.13 crore and a net profit of ₹5.54 crore, showing strong yearly and sequential growth.
Avience Biomedicals share price results
Avience Biomedicals' share price closed at ₹249.95 on November 9, 2026, near its results announcement date. The stock's performance in the week following the strong Q2 FY27 results announcement would be a key indicator of market sentiment towards the company's execution on its growth plans.